University of Texas's MD Anderson Cancer: Relatlimab Plus Nivolumab Improves Progression-Free Survival in Metastatic Melanoma
January 06, 2022
January 06, 2022
HOUSTON, Texas, Jan. 6 (TNSJou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Jan. 5, 2022:
* * *
Study establishes LAG-3 inhibition as therapeutically relevant third immune checkpoint pathway
* * *
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free survival benefit compared to nivolumab alone, wit . . .
* * *
Study establishes LAG-3 inhibition as therapeutically relevant third immune checkpoint pathway
* * *
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the progression-free survival benefit compared to nivolumab alone, wit . . .